NCT07653971尚未招募不适用
Clinical Translation and Application Protocol for ZVS101e in the Gene Therapy of Bietti Crystalline Corneoretinal Dystrophy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 300
- 试验地点
- 2
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety and early effectiveness of ZVS101e in patients with Bietti crystalline dystrophy who meet the eligibility criteria for treatment under the translational application program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
Participants will:
undergo screening and baseline assessments to confirm eligibility; receive a single subretinal injection of ZVS101e in the study eye; complete follow-up visits over 4 weeks after treatment for safety monitoring and assessment of early effectiveness.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participate in the research and sign the informed consent form, and be willing to complete the entire process according to the protocol requirements;
- •Clinically diagnosed with Bietti's Crystalline Dystrophy (BCD), age ≥ 18 years;
- •Confirmed by genetic testing to carry homozygous or compound heterozygous mutations in CYP4V2, and not complicated with other ophthalmic genetic diseases;
- •Target eye BCVA ≤ 60 ETDRS letters.
排除标准
- •Subjects will be excluded if they meet any 1 of the following exclusion criteria:
- •The target eye currently has or has a history of macular lesions; suffers from ocular diseases that may hinder surgery or interfere with the interpretation of study endpoints;
- •The target eye has previously undergone retinal reattachment surgery, vitrectomy, or any intraocular surgery within 3 months before enrollment;
- •Within 1 month before enrollment, suffered from viral infectious diseases that may affect the evaluation of the efficacy and safety of the investigational drug, or received antiviral vaccines;
- •The target eye has previously received gene therapy or stem cell therapy for BCD or other ocular diseases;
- •Known allergy to the drugs planned for use in the study;
- •The laboratory abnormalities are considered clinically significant;
- •Pregnant or lactating females.
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
1 期
Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning SurgeryParkinson's Disease (PD)NCT07550374iRegene Therapeutics Co., Ltd.10
招募中
2 期
A Study of NTX-1472 in Social Anxiety DisorderNCT07323784Newleos Therapeutics, Inc.100
招募中
2 期
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP2023-507754-33-00Medical Center - University Of Freiburg40
尚未招募
Phase 3 4
Effect of Vaitrain Basti and Anuvasana Basti With Ashtkatwar Taila in the Management Of SciaticaCTRI/2024/09/074159Dr Sarvapalli Radhakrishnan Rajasthan Ayurved University Kadwar Jodhpur Rajasthan60
招募中
1 期
A Phase 1 Study of PVT401 in Healthy SubjectsNCT07423000Parvus Therapeutics, Inc.36